Nasal immune responses to respiratory viruses in immunocompromised and healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will compare nasal mucosal immunity to respiratory viruses, including SARS-CoV-2, in immunocompromised adults and healthy volunteers aged 18–90. Researchers will collect nasal samples and perform laboratory immune measurements to characterize immune cell composition and virus-specific responses in the upper airway. The study aims to describe how specific responses develop and how long they persist in different participant groups. Findings will be used to better understand how underlying immune impairment or immunosuppressive treatments alter local antiviral immunity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Informed Consent: Participants must have signed an informed consent form.
* Age Range: Participants aged between 18 and 90 years.
* Healthy Immunocompetent Donors: no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications.
* Immunocompromised Patients: subjects with medical conditions or treatments associated with significant impairment of the immune system. This may include organ or stem cell transplants, ongoing immunosuppressive therapies, documented genetic immunosuppression.

Exclusion Criteria:

* Pregnant or lactating women.
* Individuals unable to provide informed consent

Where it's running

• Fondazione IRCCS Policlinico San Matteo di Pavia
  Pavia, Pavia, Italy Recruiting

Study contacts

• Study coordinator: Stefania Mantovani, MSc
• Email: s.mantovani@smatteo.pv.it
• Phone: 0039 0382501808

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oral switch for bloodstream infections in immunocompromised children

  This trial tests whether switching from IV to oral antibiotics is just as safe as continuing IV therapy for children with bloodstream infections who are immunocompromised or have a central venous catheter.

  Recruiting at 4 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Aalborg and 3 other locations · NCT07923266

• Immune biomarkers to predict complications after liver transplantation

  This study tests immune biomarkers in adults after liver transplant to see if changes in markers relate to infections, rejection, or viral reactivation within the first year.

  Recruiting at 3 sites Hospital Italiano de Buenos Aires · Pilar, Buenos Aires and 2 other locations · NCT07875595

• Biomarkers of Inflammation, Infection, and Immunity in Critically Ill Patients

  This study tests whether blood biomarkers can predict illness severity and complications in adults admitted to intensive care with infection, including sepsis, and in immunocompromised or high-risk surgical patients.

  Recruiting University of Turin, Italy · Torino · NCT07682766

• Personalized immunological score to predict severe infections in transplant and immunocompromised patients

  This project will test whether a personalized immunological score can predict serious infections in transplant and other immunocompromised patients and help tailor their care.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07379554

• Recombinant shingles vaccine for frail and immunocompromised adults

  This project will test whether a recombinant shingles (herpes zoster) vaccine produces protective immune responses and is safe in frail adults with weakened immune systems.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT07321808

• TASTY training to improve taste and smell for people taking tyrosine kinase inhibitors

  This trial tests whether a 12-week at-home taste and smell training program helps adults who developed taste changes after starting tyrosine kinase inhibitor treatment.

  Recruiting at 6 sites University Medical Center Groningen · Amsterdam and 10 other locations · NCT07258589

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.